| Identification | Back Directory | [Name]
LSP-249 | [CAS]
1801253-04-2 | [Synonyms]
LSP-249
N-[(6-Amino-2,4-dimethyl-3-pyridinyl)methyl]-2-[(3-chloro-6-quinolinyl)methyl]-4-pyridinecarboxamide
4-Pyridinecarboxamide, N-[(6-amino-2,4-dimethyl-3-pyridinyl)methyl]-2-[(3-chloro-6-quinolinyl)methyl]- | [Molecular Formula]
C24H22ClN5O | [MDL Number]
MFCD32671321 | [MOL File]
1801253-04-2.mol | [Molecular Weight]
431.92 |
| Hazard Information | Back Directory | [Description]
LSP-249 is a plasma kallikrein inhibitor for treatment of angioedema. | [Uses]
LSP-249 (example 35), extracted from patent WO2016011209A1, is a plasma kallikrein inhibitor under the study for angioedema, with an EC50 less than 100 nM in cell[1]. | [References]
[1] Andrew Mcdonald, et al. Therapeutic inhibitory compounds. Patent. WO2016011209A1. |
|
|